Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 12Terminated 5Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Recurrence 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Gastrointestinal Stromal Tumors 1Gastro-Intestinal Stromal Tumour 1Colorectal Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × masitinib × Clear all
NCT00812240 2023-02-01

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

AB Science

Phase 3 Terminated
335 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT01280565 2020-11-05

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

AB Science

Phase 3 Terminated
134 enrolled
Dermatologic

Melanoma

NCT02605044 2019-02-11

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

AB Science

Phase 3 Terminated
123 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

AB Science

Phase 3 Terminated
147 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02009423 2018-12-14

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

AB Science

Phase 3 Terminated
7 enrolled

Gastro-Intestinal Stromal Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡